Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With Recent Onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ladarixin (Primary)
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms GLADIATOR STUDY
Sponsors Dompe Farmaceutici

Most Recent Events

30 Jun 2024 This trial has been completed in Slovenia, according to European Clinical Trials Database record.
21 Mar 2024 Status changed from recruiting to active, no longer recruiting.
04 Oct 2023 Planned End Date changed from 1 Mar 2025 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight